BUSINESS BRIEFING / PHARMACEUTICALS
- Share via
Times Wire Reports
Healthcare giant Johnson & Johnson is jumping into the increasingly hot vaccine business by taking an 18% stake in Dutch biotechnology company Crucell and focusing more on preventive medicine.
Under the deal, Johnson & Johnson is spending 301.8 million euros ($440 million) for new shares of Crucell in a deal focused initially on developing a universal vaccine or treatment against influenza from Crucell’s genetically engineered antibody technology.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
